Selective Inhibition of Various Mitogen Responses in Human Lymphocytes

  • G. Delespesse
  • J. P. R. M. van Laarhoven
  • H. Collet
  • C. H. M. M. De Bruyn
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 165)


Adenosine and deoxyadenosine are known inhibitors of the in vitro proliferative response of peripheral blood lymphocytes(PBL) to various mitogens(1–7). Erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride (EHNA), an inhibitor of the enzyme adenosine deaminase(ADA), potentiates the inhibitory effects of both adenosine and deoxyadenosine. The incorporation of3H-leucirie into protein appeared to be a more sensitive index of adenosine toxicity than the incorporation of3H-thymidine(1). A differential sensitivity of cultured human T and B lymphoblasts towards the toxic effects of adenosine and deoxyadenosine has been observed: T cells are more sensitive than B cells(8,9). On the basis of3H-thymidine incorporation, mouse splenic cells stimulated by lipopolysaccharide(LPS) were less sensitive to the addition of adenosine than the concanavalin A(ConA) stimulated cells (10). Using a plaque forming cell assay, a biphasic effect of adenosine was seen on the in vitro antibody production in mice; concentrations of adenosine around 1mM stimulated antibody production in vitro, whereas concentrations above 1.5 mM had inhibitory effects (10).


Peripheral Blood Lymphocyte Proliferative Response Thymidine Uptake Human Peripheral Blood Lymphocyte Leucine Incorporation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D.A. Carson and J.E. Seegmiller, J. Clin. Invest., 57: 274 (1976).PubMedCrossRefGoogle Scholar
  2. 2.
    D.A. Carson, J. Kaye and J.E. Seegmiller, Proc. Natl. Acad. Sci. U.S.A., 74: 5677 (1977).PubMedCrossRefGoogle Scholar
  3. 3.
    E.W. Gelfand, J.J. Lee and H.M. Dosch, Proc. Natl. Acad. Sci. U.S.A., 76: 1998 (1979).PubMedCrossRefGoogle Scholar
  4. 4.
    K.R. Harrap and R.M. Paine, Adv. Enzyme Regul., 15: 169 (1976).PubMedCrossRefGoogle Scholar
  5. 5.
    T. Hovi, J.F. Smyth, A.C. Allison and S.C. Williams, Clin. Exp. Immunol., 23: 395 (1976).PubMedGoogle Scholar
  6. 6.
    H.A. Simmonds, G.S. Panayi and V. Corrigall, Lancet, i:60 (1978).CrossRefGoogle Scholar
  7. 7.
    S. Skupp, G. Cugrek and J.H. Ayvazian, Biochem. Pharmacol., 28: 3323 (1979).PubMedCrossRefGoogle Scholar
  8. 8.
    D.A. Carson, J. Kaye and J.E. Seegmiller, J. Immunol. 121: 1726 (1978).PubMedGoogle Scholar
  9. 9.
    B.S. Mitchell, E. Mejias, P.E. Daddona and W.N. Kelley, Proc. Natl. Acad. Sci. U.S.A. 75: 5011 (1978).PubMedCrossRefGoogle Scholar
  10. 10.
    J.E. Seegmiller, T. Watanabe and H.M. Schreier, in:“Purine and Pyrimidine Metabolism”, CIBA Foundation Symposium, Vol. 48., K. Elliot and D.W. Fitzimons, Eds., Elseviers Scientific Publishing Company, Amsterdam, (1977).Google Scholar
  11. 11.
    A. Bøyum, Scand. J. Immunol., 5, suppl. 5: 9 (1976).PubMedCrossRefGoogle Scholar
  12. 12.
    J.P.R.M. van Laarhoven, C.H.M.M. de Bruyn, H. Collet and G. Delespesse, in: Proceedings of the International Symposium on “Recent Advances on Immunomodulators”, F. Ambrogi and H. Fudenberg, Eds., Plenum Press, New York, in press.Google Scholar
  13. 13.
    S. Gupta and R.A. Good, Semin, Hematol. 17: 1 (1980).Google Scholar
  14. 14.
    H.B. Herscowitz, T. Sakane, A.D. Steinberg and I. Green, J. Immunol., 124: 1403 (1980).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • G. Delespesse
    • 1
  • J. P. R. M. van Laarhoven
    • 2
  • H. Collet
    • 1
  • C. H. M. M. De Bruyn
    • 2
  1. 1.Dept. of Immunology and Blood TransfusionUniversity Hospital St. Pierre, Free UniversityBrusselsBelgium
  2. 2.Dept. of Human Genetics, Faculty of MedicineUniversity of NijmegenNijmegenThe Netherlands

Personalised recommendations